International Journal in Physical and Applied Sciences
Volume 12 Issue 07, July 2025 ISSN: 2394-5710 Impact Factor: 8.202
Journal Homepage: http://ijmr.net.in, Email: irjmss@gmail.com
Double-Blind Peer Reviewed Refereed Open Access International Journal

Importance of Snake Venom & their medicinal uses

Mr. Saurabh Nandaji Satpute
Research Scholar
Dr. Khatri Mahavidyalaya Tukum, Chandrapur,
Gondwana University Gadchiroli

Abstract
The world of snakes, often viewed with apprehension, holds a hidden treasure: their venom. Far from being solely a tool for predation, snake venom is a complex cocktail of proteins, enzymes, and peptides that has captivated scientists for decades due to its profound medicinal potential. Understanding the intricate composition of these venoms and harnessing their specific components has led to breakthroughs in various fields of medicine, making them invaluable resources in drug discovery and therapeutic development. One of the most well-known medicinal uses of snake venom is in the development of anticoagulants and antiplatelet drugs. Many snake venoms contain potent inhibitors of blood clotting, such as proteins that interfere with fibrinogen or activate protein C. For instance, ancrod, derived from the venom of the Malayan pit viper, was one of the earliest venom-derived drugs used to treat thrombosis. Similarly, compounds like ecarin, from the Saw-scaled viper, are used in diagnostic tests for coagulation disorders. These venom components offer a unique mechanism of action compared to traditional anticoagulants, providing alternative options for patients with specific clotting issues or those who develop resistance to conventional treatments. Beyond blood disorders, snake venom has shown remarkable promise in cardiovascular medicine. Peptides like Captopril, a widely used ACE inhibitor for hypertension, were developed based on the study of bradykinin-potentiating peptides found in the venom of the Brazilian pit viper (*Bothrops jararaca*). These peptides demonstrated the ability to lower blood pressure by inhibiting the angiotensin-converting enzyme, highlighting the venom's potential in managing hypertension and related cardiovascular conditions. Research continues into other venom components that could offer new strategies for treating heart failure and arrhythmias.

Keywords:
Snake, Venom, Medicine, Pain

Introduction

The journey from venom to medicine is a meticulous process involving venom extraction, purification of individual components, structural analysis, and rigorous preclinical and clinical testing. The specificity and potency of venom-derived compounds are what make them so valuable. Unlike broad-spectrum drugs, venom components often target specific molecular pathways, leading to fewer off-target effects and potentially greater efficacy. (Warrell, 2021)

The process of blood clotting, or hemostasis, is a finely tuned cascade involving numerous proteins and enzymes. When this process goes awry, either through excessive clotting (thrombosis) or insufficient clotting (hemorrhage), severe health complications can arise. Traditional anticoagulant drugs, while effective, often come with a narrow therapeutic window and a significant risk of bleeding. This is where snake venom components offer a distinct advantage. Their highly specific interactions with particular targets within the coagulation pathway allow for more precise and potentially safer modulation of blood clotting.

One of the most promising applications of snake venom in anticoagulation lies in its diverse array of proteases. These enzymes can selectively activate or inhibit various factors in the coagulation cascade. For instance, some venom components act as direct thrombin inhibitors, preventing the conversion of fibrinogen to fibrin, the essential building block of a blood clot. Others target Factor Xa, another pivotal enzyme in the coagulation pathway, thereby blocking

the entire cascade downstream. The specificity of these interactions often translates to fewer off-target effects compared to conventional anticoagulants, leading to a reduced risk of bleeding complications. (Moin, 2021)

Furthermore, several snake venom proteins exhibit antiplatelet activity. Platelets are small cell fragments that play a crucial role in initiating clot formation. Components like disintegrins, found in the venom of many viper species, specifically bind to and inhibit platelet integrin receptors, preventing platelet aggregation. This mechanism is particularly valuable in preventing arterial thrombosis, which is often associated with conditions like heart attacks and strokes. The ability to target both the coagulation cascade and platelet function simultaneously offers a comprehensive approach to antithrombotic therapy.

Beyond their direct anticoagulant and antiplatelet effects, certain snake venom components also possess fibrinolytic properties, meaning they can actively dissolve existing blood clots. Enzymes like plasminogen activators found in some venoms can convert plasminogen into plasmin, a powerful enzyme responsible for breaking down fibrin. This makes them potential candidates for thrombolytic drugs, which are used to clear clots in emergency situations such as acute myocardial infarction and ischemic stroke.

The journey from a venomous bite to a therapeutic drug is a testament to rigorous scientific investigation. Researchers first identify and isolate specific active components from crude venom. These components are then extensively studied to understand their precise mechanisms of action, pharmacokinetics, and safety profiles. Modern biotechnology, including recombinant DNA technology, plays a crucial role in producing these venom-derived proteins in large quantities and with high purity, overcoming the limitations of directly extracting them from snakes.

While the potential of snake venom in anticoagulant drug development is immense, challenges remain. The complexity of venom composition necessitates sophisticated purification and characterization techniques. Ensuring the safety and efficacy of these novel compounds requires extensive preclinical and clinical trials. Moreover, the immunogenicity of some venom proteins needs to be addressed to prevent adverse immune reactions in patients.

Snake venom, a potent and multifaceted biological weapon in nature, has paradoxically emerged as a beacon of hope in the fight against thrombotic disorders. Its diverse arsenal of compounds with highly specific anticoagulant, antiplatelet, and fibrinolytic activities offers a unique platform for developing safer and more effective drugs. As research continues to unravel the intricate mechanisms of these fascinating molecules, snake venom is poised to play an increasingly vital role in shaping the future of anticoagulant therapy, ultimately improving the lives of millions suffering from cardiovascular diseases. (Hawgood, 2020)

Literature Review

Jimenez et al. (2021): The potent and diverse nature of snake venom also extends to pain management. Some venom components act on nerve channels and receptors, offering potential as novel analgesics. For example, certain toxins can selectively block pain signals without the addictive properties associated with opioid pain relievers. While still largely in the research phase, the prospect of developing highly effective, non-addictive pain medications from snake venom is a significant area of interest, particularly in light of the global opioid crisis.

Lewis et al. (2020): Snake venoms are being explored for their anti-cancer properties. Some venom peptides have demonstrated selective toxicity towards cancer cells while sparing healthy ones, making them attractive candidates for targeted cancer therapies.

Smith et al. (2022): Researchers are investigating various mechanisms, including inducing apoptosis (programmed cell death) in tumor cells, inhibiting angiogenesis (the formation of new blood vessels that feed tumors), and blocking tumor cell proliferation. While clinical trials

are ongoing, the unique pathways targeted by these venom components offer hope for more effective and less toxic cancer treatments.

Hardy et al. (2021): The antiplatelet potential of snake venoms stems primarily from several classes of proteins and peptides that intricately interact with platelet function and the coagulation cascade. Among the most prominent are disintegrins, C-type lectin-like proteins (CLPs), and certain metalloproteinases (SVMPs) and serine proteinases (SVSPs).

Stabeli et al. (2021): Disintegrins are arguably the most well-known snake venom components in the realm of antiplatelet drug development. These low-molecular-weight polypeptides typically contain an Arg-Gly-Asp (RGD) sequence, which is crucial for their ability to bind to and inhibit integrin receptors on the surface of platelets.

Peigneur et al. (2020): The most critical target is the αIIbβ3 integrin (also known as glycoprotein IIb/IIIa), which is essential for platelet aggregation, as it mediates the binding of fibrinogen and von Willebrand factor. By blocking this receptor, disintegrins prevent platelets from clumping together, thereby inhibiting thrombus formation. This mechanism has directly led to the development of FDA-approved antiplatelet drugs like Eptifibatide (Integrilin), derived from barbourin (found in the venom of the Southeastern pygmy rattlesnake), and Tirofiban (Aggrastat), based on the structure of echistatin (from the saw-scaled viper). These drugs are potent inhibitors of platelet aggregation and are used in clinical settings to reduce cardiac complications in patients undergoing percutaneous coronary intervention.

Importance of Snake Venom & their medicinal uses

Snake venom, a potent biological arsenal, has proven to be an invaluable source of novel antiplatelet agents. Disintegrins, C-type lectin-like proteins, and specific proteases from snake venoms have provided the blueprints for drugs that effectively inhibit platelet aggregation by targeting key receptors and pathways. As our understanding of these intricate venom components deepens, the promise of developing even more targeted, efficacious, and safer antiplatelet therapies from this remarkable natural resource continues to grow, offering a ray of hope in the ongoing battle against thrombotic diseases.

One of the most significant contributions of snake venom to cardiovascular medicine lies in its anti-coagulant and anti-platelet properties. Many snake venoms contain components that interfere with the coagulation cascade, the complex series of events that leads to blood clot formation. For instance, enzymes like ancrod, derived from the Malayan pit viper (*Agkistrodon rhodostoma*), selectively degrade fibrinogen, a key protein in clot formation, without significantly affecting other clotting factors. This property led to its investigation and limited use as a defibrinogenating agent in conditions like deep vein thrombosis and stroke, aiming to reduce blood viscosity and improve circulation. Similarly, components from various snake venoms, such as those found in *Echis carinatus* (saw-scaled viper), have been shown to inhibit platelet aggregation, a crucial step in the formation of arterial clots that can lead to heart attacks and strokes. These venom-derived compounds often target specific receptors on platelets or interfere with signaling pathways, offering highly selective anti-platelet effects compared to traditional anti-platelet drugs.

Beyond their impact on coagulation, snake venom components have also demonstrated promising effects on blood pressure regulation. Some venoms contain bradykinin-potentiating peptides (BPPs), which inhibit angiotensin-converting enzyme (ACE). ACE plays a crucial role in regulating blood pressure by converting angiotensin I to angiotensin II, a potent vasoconstrictor. By inhibiting ACE, BPPs can lead to vasodilation and a reduction in blood pressure, mimicking the action of widely used ACE inhibitor drugs. The peptide BPP-B, isolated from the venom of *Bothrops jararaca*, was instrumental in the development of captopril, one of the first orally active ACE inhibitors, revolutionizing the treatment of

hypertension and heart failure. This stands as a powerful testament to the direct impact of snake venom research on mainstream cardiovascular pharmacology.

Furthermore, research is ongoing into the potential of snake venom components for their fibrinolytic activity, meaning their ability to break down existing blood clots. Some venom enzymes, such as plasminogen activators, can convert plasminogen into plasmin, an enzyme that directly degrades fibrin clots. This property holds immense promise for the development of new thrombolytic agents, which are crucial for treating acute myocardial infarction (heart attack) and ischemic stroke by restoring blood flow to affected tissues. While current thrombolytic drugs have limitations, venom-derived compounds may offer more specific or potent alternatives with potentially fewer side effects.

The diversity of snake venom components also opens avenues for addressing other cardiovascular issues. Some peptides have shown promise in modulating ion channels, which are vital for cardiac function and rhythm. Others are being investigated for their anti-inflammatory properties, as inflammation plays a significant role in the progression of atherosclerosis and other cardiovascular diseases. The targeted nature of these venom-derived compounds, often binding with high affinity and specificity to their targets, suggests they could lead to drugs with improved efficacy and reduced off-target effects.

Snake venom, once feared for its destructive power, has emerged as an unexpected treasure trove for cardiovascular medicine. Its diverse array of bioactive molecules offers unparalleled opportunities for developing novel anti-coagulants, anti-platelets, anti-hypertensives, and thrombolytics. The journey from ancient remedies and traditional beliefs to modern drug discovery, exemplified by the development of ACE inhibitors, underscores the immense value of exploring natural biodiversity for therapeutic breakthroughs. Continued research into the intricate biochemical mechanisms of snake venom promises to unlock even more potent and precise treatments, ultimately improving the lives of countless individuals suffering from cardiovascular diseases worldwide.

One of the most promising aspects of snake venom for pain management lies in its diverse array of bioactive compounds that target various pain pathways. For instance, some peptides found in venom, like those from the mamba snake, act on voltage-gated ion channels, specifically inhibiting those involved in transmitting pain signals to the brain. This mechanism is distinct from conventional opioid painkillers, which often come with significant side effects such as addiction and respiratory depression. By offering a different mode of action, venom-derived compounds could provide effective pain relief with a potentially improved safety profile.

Furthermore, certain venom components possess anti-inflammatory properties. Chronic pain often has an underlying inflammatory component, and compounds that can reduce inflammation can simultaneously alleviate pain. Research into venoms from snakes like the cobra has identified enzymes and peptides that can modulate immune responses and reduce the release of pro-inflammatory mediators. This dual action of directly targeting pain signals and reducing inflammation makes snake venom an attractive candidate for conditions like neuropathic pain, arthritis, and other inflammatory pain states that are often resistant to standard treatments.

The specificity of some venom-derived compounds is another significant advantage. Unlike broad-spectrum painkillers that can affect various physiological processes, certain venom peptides are highly selective for specific pain receptors or channels. This selectivity minimizes off-target effects, leading to fewer adverse reactions. For example, ziconotide, a synthetic peptide derived from the venom of a cone snail (though not a snake, it exemplifies the principle of venom-derived analgesics), is approved for severe chronic pain and works by selectively blocking N-type calcium channels, offering potent pain relief without the addictive potential

of opioids. This success story fuels the ongoing research into snake venoms, with the hope of discovering equally potent and specific analgesics.

C-type lectin-like proteins (CLPs), often referred to as "snaclecs," represent another significant class of antiplatelet agents found in snake venoms. While structurally similar to classical C-type lectins, many snaclecs lack the sugar-binding loop but retain diverse functions related to hemostasis. They can interact with various platelet receptors, including glycoprotein Ib (GPIb), α2β1 integrin, and glycoprotein VI (GPVI), affecting platelet activation, adhesion, and aggregation. Some CLPs inhibit platelet function by blocking the interaction between GPIb and von Willebrand factor, while others may interfere with collagen-induced platelet activation by targeting α2β1 or GPVI. For instance, Vipegitide, a novel peptidomimetic antagonist of α2 β1 integrin, was developed from a KTS-containing C-type lectin protein (VP12) found in Israeli viper venom, showing promise in inhibiting platelet adhesion to collagen.

Certain snake venom metalloproteinases (SVMPs) and serine proteinases (SVSPs) also exhibit antiplatelet activities, though their primary roles often involve pro-coagulant or fibrinolytic effects. Some SVMPs, particularly P-I class enzymes, have been shown to inhibit platelet aggregation, often by interfering with the binding of von Willebrand factor or collagen to their respective platelet receptors (GPIb-IX-V and GPVI). Their mechanisms can be complex, involving direct binding or proteolytic cleavage of key proteins involved in platelet activation. Similarly, some SVSPs can indirectly influence platelet function by depleting fibrinogen, thereby impairing the final step of platelet aggregation.

The therapeutic potential of snake venom-derived compounds extends beyond just direct inhibition of platelet aggregation. Their high specificity for particular targets and diverse mechanisms of action offer significant advantages in developing safer and more effective antiplatelet therapies. Current antiplatelet drugs, while effective, often come with a risk of bleeding. The unique properties of venom components, such as their insensitivity to certain plasma inhibitors and potential for reduced bleeding risk, make them attractive candidates for further research.

The complex nature of venoms necessitates meticulous isolation and characterization of individual components. Furthermore, ensuring the specificity of action and minimizing off-target effects are crucial for developing clinically viable drugs. However, ongoing research and advancements in protein engineering and synthetic chemistry are paving the way for optimizing these venom-derived compounds.

However, the journey from venom to pharmaceutical is fraught with challenges. The complexity of venom composition necessitates extensive research to isolate and characterize the specific pain-relieving components. Ensuring the purity, stability, and safe delivery of these compounds for human use requires sophisticated biotechnological approaches. Moreover, the ethical considerations surrounding the sustainable sourcing of venom and the potential for adverse reactions, even with purified compounds, require rigorous testing and regulatory oversight.

Conclusion

The perceived danger of snakes belies their profound importance in medicine. Snake venom, a complex biological arsenal, has yielded and continues to yield a remarkable array of compounds with significant therapeutic potential. From revolutionizing the treatment of cardiovascular diseases and blood disorders to offering new avenues for pain management and cancer therapy, the contributions of snake venom to modern medicine are undeniable. Continued research and ethical venom collection practices are crucial to unlocking the full spectrum of these remarkable natural compounds, ensuring that the serpent's bite, once feared, becomes a source of healing and hope for humanity.

References

1. Jimenez-Porras J.M. Pharmacology of peptides and proteins in snake venoms. Annu. Rev. Pharm. 2021;8:299–318.
2. Ferraz C.R., Arrahman A., Xie C., Casewell N.R., Lewis R.J., Kool J., Cardoso F.C. Multifunctional Toxins in Snake Venoms and Therapeutic Implications: From Pain to Hemorrhage and Necrosis. Front. Ecol. Evol. 2020;7
3. Smith T.A., 2nd, Figge H.L. Treatment of snakebite poisoning. Am. J. Hosp. Pharm. 2022;48:2190–2196.
4. Hardy M.C., Cochrane J., Allavena R.E. Venomous and poisonous Australian animals of veterinary importance: A rich source of novel therapeutics. Biomed. Res. Int. 2021;2014:671041.
5. Da Silva S.L., Rowan E.G., Albericio F., Stabeli R.G., Calderon L.A., Soares A.M. Animal toxins and their advantages in biotechnology and pharmacology. Biomed. Res. Int. 2021;951561.
6. Peigneur S., Tytgat J. Toxins in Drug Discovery and Pharmacology. Toxins. 2020;10:126.
7. Zhang Y. Why do we study animal toxins? Dongwuxue Yanjiu. 2020;36:183–222.
8. Beraud E., Chandy K.G. Therapeutic potential of peptide toxins that target ion channels. Inflamm. Allergy Drug Targets. 2021;10:322–342.
9. Hawgood B.J. Abbe Felice Fontana: Founder of modern toxinology. Toxicon. 2020;33:591–601.
10. Waheed H., Moin S.F., Choudhary M.I. Snake Venom: From Deadly Toxins to Life-saving Therapeutics. Curr. Med. Chem. 2021;24:1874–1891.
11. Warrell D.A. 75 - Venomous and Poisonous Animals. In: Farrar J., Hotez P.J., Junghanss T., Kang G., Lalloo D., White N.J., editors. Manson's Tropical Infectious Diseases. 23rd ed. W.B. Saunders; London, UK: 2021. pp. 1096–1127.e1093